Emirates Oncology Society shared on LinkedIn:
“Join EOS for an insightful session with Dr. Aref Chehal, as he presents the exploratory biomarker analysis of the Phase 3 KEYNOTE-522 study on neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC) during the Best of SABCS UAE!
Date: Saturday, February 8, 2025
Location: Anantara, Downtown Dubai, UAE
Register now!
Find the Registration link in the BIO.
This exclusive event by EOS and Emirates Breast Cancer Working Group!”
